Asian Pacific Journal of Cancer Prevention

아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Correlates of Lymphedema in Women with Breast Cancer: a Case Control Study in Shiraz, Southern Iran

  • Honarvar, Behnam (Health Policy Research Center, Shiraz University of Medical Sciences) ;
  • Sayar, Negin (Health Policy Research Center, Shiraz University of Medical Sciences) ;
  • Tahmasebi, Sedigheh (Lymphedema Clinic, Breast Diseases Research Center, Shiraz University of Medical Sciences) ;
  • Zakeri, Zeinab (Lymphedema Clinic, Breast Diseases Research Center, Shiraz University of Medical Sciences) ;
  • Talei, Asra (Lymphedema Clinic, Breast Diseases Research Center, Shiraz University of Medical Sciences) ;
  • Rostami, Sara (Health Policy Research Center, Shiraz University of Medical Sciences) ;
  • Khademi, Sahar (Health Policy Research Center, Shiraz University of Medical Sciences) ;
  • Sarvestani, Amene Sabzi (Health Policy Research Center, Shiraz University of Medical Sciences) ;
  • Sekhavati, Eghbal (Larestan School of Medical Sciences)
  • 발행 : 2016.06.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Globally, the burden of breast cancer (BC) continues to increase. BC related lymphedema (BCRL) is currently non curable and as a life time risk it affects at least 25% of BC patients. Knowing more about BCRL and appropriate control of its modifiable risk factors can improve quality of life (QOL) of the affected patients. In this case control study to detect factors, 400 women with BCRL (as the case group) and 283 patients with BC without lymphedema (as the control group) that were referred to Shiraz University of Medical Sciences affiliated BC clinic center were assessed. The data were analyzed in SPSS. The mean age of the case group was $52.3{\pm}11.0years$ and of the control group was $50.1{\pm}10.9years$. In patients with BCRL, 203(50.7%) had left (Lt) side BC and in non- lymphedema group 151 (53.3%) had Lt side BC. Out of all BCRL patients, 204 (51%) had lymphedema in all parts of their affected upper extremities, 100 (25%) had swelling in the arm and forearm and 23 (5.7%) had edema in both the upper extremity and trunk. Edema, heaviness, concern about changing body image, pain and paresthesia were the most common signs/symptoms among patients with BCRL. In BCRL patients, the difference of circumference between the affected upper limb and non-affected limb was $4.4{\pm}2.5cm$ and the difference in volume displacement was $528.7{\pm}374.4milliliters$. Multiple variable analysis showed that moderate to severe activity (OR; odds ratio =14, 95% CI :2.6-73.3), invasiveness of BC (OR =13.7, 95% CI :7.3-25.6), modified radical mastectomy (OR=4.3, 95% CI :2.3-7.9), BMI =>25 (OR=4.2, 95% CI :2-8.7), radiotherapy (OR=3.9, 95% CI :1.8-8.2), past history of limb damage (OR=1.7, 95% CI :0.9-3.1) and the number of excised lymph nodes (OR=1.06, 95% CI :1.02-1.09) were the significant predictors of lymphedema in women with BC. Modifiable risk factors of BCRL such as non-guided moderate to severe physical activity, high BMI and trauma to the limb should be controlled as early as possible in BC patients to prevent development of BCRL and improve QOL of these patients.

키워드

참고문헌

  1. Afsharfard A, Mozaffar M, Orang E, et al (2013). Trends in epidemiology, clinical and histopathological characteristics of breast cancer in Iran: results of a 17 year study. Asian Pac J Cancer Prev, 14, 6905-11. https://doi.org/10.7314/APJCP.2013.14.11.6905
  2. Alcorso J, Sherman KA (2015). Factors associated with psychological distress in women with breast cancer-related lymphoedema. Psychooncology, 22, 1466-84.
  3. Das N, Baumgartner RN, Riley EC, et al (2015). Treatment-related risk factors for arm lymphedema among long-term breast cancer survivors. J Cancer Surviv, 9, 422-30. https://doi.org/10.1007/s11764-014-0416-9
  4. Disipio T, Rye S, Newman B, et al (2013). Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol, 14, 500-15. https://doi.org/10.1016/S1470-2045(13)70076-7
  5. Fu MR (2014). Breast cancer-related lymphedema: Symptoms, diagnosis, risk reduction, and management. World J Clin Oncol, 5, 241-7. https://doi.org/10.5306/wjco.v5.i3.241
  6. Golshan M, Smith B (2006). Prevention and management of arm lymphedema in the patient with breast cancer. J Support Oncol, 4, 381-6.
  7. Haghighat S, Akbari ME, Ghaffari S, et al (2012). Standardized breast cancer mortality rate compared to the general female population of Iran. Asian Pac J Cancer Prev, 13, 5525-8. https://doi.org/10.7314/APJCP.2012.13.11.5525
  8. Honarvar B, Lankarani KB, Rostami S, et al (2015). Knowledge and practice of people toward their rights in urban family physician program: a population-based study in Shiraz, Southern Iran. Int J Prev Med, 4, 46.
  9. Iuchi T, Dai M, Sanada H, et al (2015).Associations between the treatments and outcomes of patients with upper and lower lymphoedema in Japan: a cross-sectional observational study. Int J Nurs Stud, 52, 913-9. https://doi.org/10.1016/j.ijnurstu.2015.01.011
  10. Jassim GA, Whitford Dl , Hickey A,Carter B, et al (2015). Psychological interventions for women with non-metastatic breast cancer. Cochrane Database Syst Rev, 28, 5.
  11. Lankarani KB, Khosravizadegan Z,Rezaianzadeh A, Honarvar B, et al (2013). Data coverage of a cancer registry in southern Iran before and after implementation of a population-based reporting system: a 10-year trend study. BMC Health Serv Res, 6, 169.
  12. McNeely ML, Magee DJ , Lees AW, Bagnall KM, et al (2004). The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat, 86, 95-106. https://doi.org/10.1023/B:BREA.0000032978.67677.9f
  13. Merchant SJ, Chen SL (2015). Prevention and management of lymphedema after breast cancer treatment. Breast J, 21, 276-84. https://doi.org/10.1111/tbj.12391
  14. Mete Civelek G, Aypak C, Turedi O (2015). Knowledge of primary care physicians about breast-cancer-related lymphedema: Turkish perspective. J Cancer Educ, 4, 217-20.
  15. Michael S, Charikleia S, Konstantinos K (2011). Lymphedema and breast cancer: A review of the literature. Br J Cancer, 18, 174-80. https://doi.org/10.1007/s12282-010-0246-1
  16. Naderimagham S, Alipour S, Djalalinia S, et al (2014). National and sub-national burden of breast cancer in Iran; 1990-2013. Arch Iran Med, 17, 794-9.
  17. Sadjadi A, Nouraie M, Ghorbani A, et al (2009). Epidemiology of breast cancer in the Islamic Republic of Iran: first results from a population-based cancer registry. East. Mediterr. health j, 15, 1426-31.
  18. Taghian NR, Miller CL, Jammallo LS, et al (2014). Lymphedema following breast cancer treatment and impact on quality of life: a review. Crit Rev Oncol Hematol, 92, 227-34. https://doi.org/10.1016/j.critrevonc.2014.06.004
  19. Voss RK, Cromwell KD, Chiang YJ, et al (2015). The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients. J Surg Oncol, 112, 834-40. https://doi.org/10.1002/jso.24068
  20. Zhu YQ, Xie YH, Liu FH, et al (2014). Systemic analysis on risk factors for breast cancer related lymphedema. Asian Pac J Cancer Prev, 15, 6535-41. https://doi.org/10.7314/APJCP.2014.15.16.6535